This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

The Essential Biotech Sector Fall Preview

Biotech is very much driven by stock-specific catalysts like clinical trial results and FDA drug approvals, so a good showing for the last three months of the year will also hinge on the outcome of some key events.

Here is a list of the biotech events with the most potential impact for the remainder of 2010:

  • The FDA advisory panel for Arena Pharmaceuticals' (ARNA - Get Report) obesity drug lorcaserin on Sept. 16.
  • Amgen's results from a phase III study of denosumab in the prevention of prostate cancer.
  • Genzyme's ongoing M&A dance with Sanofi.
  • Presentation of hepatitis C drug data from Vertex Pharmaceuticals and Merck (MRK) at the American Association for the Study of Liver Disease annual meeting in November.
  • FDA's approval decision for Human Genome Sciences' (HGSI) lupus drug Benlysta on Dec. 9.
  • Likewise, the FDA's expected approval decision on Oct. 22 for the diabetes drug Bydureon from Amylin Pharmaceuticals (AMLN), Eli Lilly (LLY) and Alkermes (ALKS).
  • Medicare's national coverage determination meeting for Dendreon's prostate cancer vaccine Provenge on Nov. 17.
I previously put together a list of 21 drugs facing FDA approval decisions through the end of the year, so please check it out.

Here, too, is a list of important clinical trial results pending in 2010 and a calendar of biotech events for September.

--Written by Adam Feuerstein in Boston.



>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein.

>To submit a news tip, send an email to: tips@thestreet.com.

Adam Feuerstein writes regularly for TheStreet.com. In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet.com. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.
3 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
ARNA $4.34 2.80%
DNDN $0.06 -6.02%
IDIX $24.50 0.20%
PCYC $256.90 0.03%
AAPL $131.43 -0.92%

Markets

DOW 18,070.79 +32.82 0.18%
S&P 500 2,105.45 -3.47 -0.16%
NASDAQ 5,045.7280 -14.5180 -0.29%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs